(Hong Kong, 23 June 2006) - Lee's Pharmaceutical Holdings Limited (GEM Stock: 8221: Website: www.leespharm.com ) today announced that the application for a clinical study for the HIBOR® (Bemiparin Sodium) has been approved by the SFDA of China.